These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38710206)

  • 41. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
    Dubé S; Dellva MA; Jones M; Kielbasa W; Padich R; Saha A; Rao P
    J Psychiatr Res; 2010 Apr; 44(6):356-63. PubMed ID: 19909980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    Burke WJ; Gergel I; Bose A
    J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study.
    Altamura AC; Dell'Osso B; Buoli M; Zanoni S; Mundo E
    J Clin Psychopharmacol; 2008 Aug; 28(4):406-10. PubMed ID: 18626267
    [TBL] [Abstract][Full Text] [Related]  

  • 46. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.
    Papakostas GI; Mischoulon D; Shyu I; Alpert JE; Fava M
    Am J Psychiatry; 2010 Aug; 167(8):942-8. PubMed ID: 20595412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels.
    Khan A; Khan SR; Hobus J; Faucett J; Mehra V; Giller EL; Rudolph RL
    J Psychiatr Res; 2011 Nov; 45(11):1489-96. PubMed ID: 21752394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
    Möller HJ; Demyttenaere K; Olausson B; Szamosi J; Wilson E; Hosford D; Dunbar G; Tummala R; Eriksson H
    World J Biol Psychiatry; 2015 Oct; 16(7):483-501. PubMed ID: 25602163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
    Zhou J; Wang W; Yang J; Zhu X; Feng L; Xiao L; Wang G
    Trials; 2019 Jan; 20(1):33. PubMed ID: 30626409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
    Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
    Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
    J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial.
    Talaei A; Hassanpour Moghadam M; Sajadi Tabassi SA; Mohajeri SA
    J Affect Disord; 2015 Mar; 174():51-6. PubMed ID: 25484177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment.
    Siegel AN; Rodrigues N; Nasri F; Wilkialis L; Lipsitz O; Lee Y; Gill H; Subramaniapillai M; Phan L; Majeed A; Lui LMW; Rashidian H; Ho R; Toma S; Goldstein BI; Mansur RB; McIntyre RS; Rosenblat JD
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110032. PubMed ID: 32634540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-controlled trial.
    Yasrebi SO; Momtazmanesh S; Moghaddam HS; Shahmansouri N; Mehrpooya M; Arbabi M; Ghazizadeh-Hashemi F; Akhondzadeh S
    J Psychosom Res; 2021 Nov; 150():110635. PubMed ID: 34627009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.
    Matrisciano F; Bonaccorso S; Ricciardi A; Scaccianoce S; Panaccione I; Wang L; Ruberto A; Tatarelli R; Nicoletti F; Girardi P; Shelton RC
    J Psychiatr Res; 2009 Jan; 43(3):247-54. PubMed ID: 18511076
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Earley WR; Guo H; Németh G; Harsányi J; Thase ME
    Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
    Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
    Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.